FUJIFILM Holdings Corporation has identified “Health” as one of the priority areas in its corporate social responsibility (CSR) plan “Sustainable Value Plan 2030” ending March 2031. As part of the Company’s health goals, Fujifilm will improve access to healthcare and medicine around the world through our cutting-edge products and services across prevention, diagnosis and treatment.
Fujifilm issues a social bond offering and it is used to finance the Company’s biopharmaceutical contract development and manufacturing business (Bio CDMO* business), which contributes to fulfilling unmet medical needs and improving medical accessibility across the globe.
*Abbreviation for Contract Development & Manufacturing Organization. Providing pharmaceutical companies with various services such as cell line development in early development stage, production process development, stability testing, development and manufacturing of investigational drugs and manufacturing of commercial drugs.
|
|
Name |
FUJIFILM Holdings Corporation 20th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
FUJIFILM Holdings Corporation 21st Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
FUJIFILM Holdings Corporation 22nd Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
FUJIFILM Holdings Corporation 23rd Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
|
Timing of issue |
July 19, 2024 |
|||
|
Launch date |
July 12, 2024 |
|||
|
Maturity |
3 years |
5 years |
7 years |
10 years |
|
Issue amount |
70 billion yen |
80 billion yen |
20 billion yen |
30 billion yen |
|
Interest rate |
0.633% |
0.838% |
1.039% |
1.386% |
|
Use of proceeds |
Refinance existing investments related to building new manufacturing bases and capital investment for production capacity enhancement, on Bio CDMO business |
|||
|
Lead managers |
Daiwa Securities Co. Ltd. (book runner) Nomura Securities Co., Ltd. SMBC Nikko Securities Inc. Mizuho Securities Co., Ltd. |
|||
|
Structuring agent |
Daiwa Securities Co. Ltd. |
|||
|
Second party opinoin |
DNV Business Assurance Japan K.K. |
|||
|
Credit ratings |
AA(R&I)、A2(MDY) |
|||
|
|
Name |
FUJIFILM Holdings Corporation 16th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
FUJIFILM Holdings Corporation 17th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
FUJIFILM Holdings Corporation 18th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
FUJIFILM Holdings Corporation 19th Series of Unsecured Corporate Bonds (with inter-bond pari passu clause) (Social bonds) |
|
Timing of issue |
April 20, 2022 |
|||
|
Launch date |
April 14, 2022 |
|||
|
Maturity |
3 years |
5 years |
7 years |
10 years |
|
Issue amount |
40 billion yen |
40 billion yen |
20 billion yen |
20 billion yen |
|
Interest rate |
0.100% |
0.195% |
0.304% |
0.374% |
|
Use of proceeds |
Refinance existing investments related to capital investments for new manufacturing sites, M&A, manufacturing capacity expansion and development for high-efficiency and high-productivity technologies, etc., on Bio CDMO business |
|||
|
Lead managers |
Daiwa Securities Co. Ltd. (book runner) Nomura Securities Co., Ltd. Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. |
|||
|
Structuring agent |
Daiwa Securities Co. Ltd. |
|||
|
Second party opinoin |
DNV Business Assurance Japan K.K. |
|||
|
Credit ratings |
AA(R&I)、A2(MDY) |
|||
April 24, 2024
|
Issuance Amount |
Allocated Amount |
Unallocated Amount |
Ratio of Refinance |
|
JPY 120 billion |
JPY 120 billion |
JPY 0 billion |
100％ |
|
Eligibility Criteria |
Eligible Project |
Allocated Amount |
|
Building new manufacturing bases, M&A, capital investment for production capacity enhancement, development for high efficiency and high productivity technologies, etc. , on Bio CDMO business |
①Acquisition of Denmark manufacturing site（FUJIFILM Diosynth Biotechnologies Denmark ApS）from Biogen |
Approx. $ 890 million |
|
②Capacity expansion of Denmark manufacturing site (expansion of six 20 kl culture tanks (total 120 kl), etc.) |
Approx. JPY 20 billion |
|
|
Total Amount：JPY 120 billion |
April 24, 2024
|
Social Project Category |
Eligibility Criteria |
Target Population |
Outcome |
Impact |
|
Access to essential services (health, healthcare) |
Building new manufacturing bases, M&A, capital investment for production capacity enhancement, development for high efficiency and high productivity technologies, etc. , on Bio CDMO business |
Biopharmaceutical users |
Production capacity of our Bio CDMO business： 180Kℓ （As of March 2024） |
Satisfying unmet medical needs and improving access to medical services through stable supply of high-quality bio pharmaceuticals |